About C4 Therapeutics
C4 Therapeutics is a company based in Cambridge (United States) founded in 2016 by Marc A Cohen.. C4 Therapeutics has raised $223 million across 4 funding rounds from investors including Novartis, Janus Henderson Investors and RTW Investments. The company has 110 employees as of December 31, 2024. C4 Therapeutics offers products and services including Cemsidomide, CFT1946, and CFT8919. C4 Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Erasca, MiRagen, Mereo BioPharma and Nimbus Therapeutics, among others.
- Headquarter Cambridge, United States
- Employees 110 as on 31 Dec, 2024
- Founders Marc A Cohen
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name C4 Therapeutics, Inc.
-
Annual Revenue
$35.58 M71.44as on Dec 31, 2024
-
Net Profit
$-105.32 M20.51as on Dec 31, 2024
-
EBITDA
$-109.28 M16.76as on Dec 31, 2024
-
Total Equity Funding
$223 M (USD)
in 4 rounds
-
Latest Funding Round
$25 M (USD), Post-IPO
Jan 04, 2024
-
Investors
Novartis
& 23 more
-
Employee Count
110
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of C4 Therapeutics
C4 Therapeutics is a publicly listed company on the NASDAQ with ticker symbol CCCC in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of C4 Therapeutics
C4 Therapeutics offers a comprehensive portfolio of products and services, including Cemsidomide, CFT1946, and CFT8919. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Therapy that degrades proteins to treat diseases.
Protein degradation treatment for targeted medical applications.
Innovative drug using protein degradation for disease management.
Unlock access to complete
Unlock access to complete
Leadership Team
35 people
Software Development Team
10 people
Clinical Team
4 people
Scientific Team
4 people
Human Resources and Administration
3 people
Legal and Compliance
2 people
Senior Team
2 people
Principal Team
1 people
Unlock access to complete
Funding Insights of C4 Therapeutics
C4 Therapeutics has successfully raised a total of $223M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Post-IPO — $25.0M
-
First Round
First Round
(07 Jan 2016)
- Investors Count 24
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2024 | Amount | Post-IPO - C4 Therapeutics | Valuation |
investors |
|
| Jun, 2020 | Amount | Debt – Venture - C4 Therapeutics | Valuation |
investors |
|
| Jun, 2020 | Amount | Series B - C4 Therapeutics | Valuation | Cobro Ventures , Perceptive Advisors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in C4 Therapeutics
C4 Therapeutics has secured backing from 24 investors, including institutional and venture fund investors. Prominent investors backing the company include Novartis, Janus Henderson Investors and RTW Investments. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health-tech companies are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
Investment firm backed by the Cohen family
|
Founded Year | Domain | Location | |
|
Early-stage investments are targeted by Axil Capital, a VC firm.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by C4 Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - C4 Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
C4 Therapeutics Comparisons
Competitors of C4 Therapeutics
C4 Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Erasca, MiRagen, Mereo BioPharma and Nimbus Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on C4 Therapeutics
Frequently Asked Questions about C4 Therapeutics
When was C4 Therapeutics founded?
C4 Therapeutics was founded in 2016.
Where is C4 Therapeutics located?
C4 Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Is C4 Therapeutics a funded company?
C4 Therapeutics is a funded company, having raised a total of $223M across 4 funding rounds to date. The company's 1st funding round was a Debt – Venture of $20M, raised on Jan 07, 2016.
How many employees does C4 Therapeutics have?
As of Dec 31, 2024, the latest employee count at C4 Therapeutics is 110.
What is the annual revenue of C4 Therapeutics?
Annual revenue of C4 Therapeutics is $35.58M as on Dec 31, 2024.
What does C4 Therapeutics do?
C4 Therapeutics was established in 2016 and is based in Cambridge, United States. Focus is placed on the biotechnology sector, where small-molecule therapeutics are created to address cancer. The Degronimid platform is employed to design binders that selectively target problematic proteins, enabling their degradation through the cellular proteasome pathway. Development efforts include CFT7455 aimed at hematologic malignancies, CFT8634 for sarcoma, and a BRAF V600E inhibitor for solid tumors.
Who are the top competitors of C4 Therapeutics?
C4 Therapeutics's top competitors include Jazz Pharmaceuticals, Erasca and Nimbus Therapeutics.
What products or services does C4 Therapeutics offer?
C4 Therapeutics offers Cemsidomide, CFT1946, and CFT8919.
Is C4 Therapeutics publicly traded?
Yes, C4 Therapeutics is publicly traded on NASDAQ under the ticker symbol CCCC.
Who are C4 Therapeutics's investors?
C4 Therapeutics has 24 investors. Key investors include Novartis, Janus Henderson Investors, RTW Investments, RA Capital, and Perceptive Advisors.
What is C4 Therapeutics's ticker symbol?
The ticker symbol of C4 Therapeutics is CCCC on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.